Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design - Wikidata - wikimedia - TriplyDB

Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design

Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design

http://www.wikidata.org/entity/Q27644634

about

HIV-Host Interactions: Implications for Vaccine Design Vaccine-Induced Antibodies that Neutralize Group 1 and Group 2 Influenza A Viruses Trimeric HIV-1-Env Structures Define Glycan Shields from Clades A, B, and G Somatic Hypermutation-Induced Changes in the Structure and Dynamics of HIV-1 Broadly Neutralizing Antibodies Cross-Neutralizing Antibodies in HIV-1 Individuals Infected by Subtypes B, F1, C or the B/Bbr Variant in Relation to the Genetics and Biochemical Characteristics of the env Gene What Are the Most Powerful Immunogen Design Vaccine Strategies?Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.Asymmetric recognition of HIV-1 Envelope trimer by V1V2 loop-targeting antibodies.A Broadly Neutralizing Antibody Targets the Dynamic HIV Envelope Trimer Apex via a Long, Rigidified, and Anionic β-Hairpin Structure.Effect of Glycosylation on an Immunodominant Region in the V1V2 Variable Domain of the HIV-1 Envelope gp120 Protein.Antibodyomics: bioinformatics technologies for understanding B-cell immunity to HIV-1.Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial.Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques Detection of Broadly Neutralizing Activity within the First Months of HIV-1 Infection.Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.SONAR: A High-Throughput Pipeline for Inferring Antibody Ontogenies from Longitudinal Sequencing of B Cell Transcripts.HIV Vaccine Design to Target Germline Precursors of Glycan-Dependent Broadly Neutralizing Antibodies.Epitope-Independent Purification of Native-Like Envelope Trimers from Diverse HIV-1 Isolates.Optimal immunization cocktails can promote induction of broadly neutralizing Abs against highly mutable pathogens.Cryo-EM structure of a CD4-bound open HIV-1 envelope trimer reveals structural rearrangements of the gp120 V1V2 loop.Promise and problems associated with the use of recombinant AAV for the delivery of anti-HIV antibodies Native-like Env trimers as a platform for HIV-1 vaccine design.Ontogeny-based immunogens for the induction of V2-directed HIV broadly neutralizing antibodies.Germline-targeting immunogens.Antigenic landscape of the HIV-1 envelope and new immunological concepts defined by HIV-1 broadly neutralizing antibodies.Approaches to the induction of HIV broadly neutralizing antibodies.Evolution of B cell analysis and Env trimer redesign.Polyvalent vaccine approaches to combat HIV-1 diversity Antibody-virus co-evolution in HIV infection: paths for HIV vaccine development.Identification and specificity of broadly neutralizing antibodies against HIV Towards functional antibody-based vaccines to prevent pre-erythrocytic malaria infection.How HIV-1 entry mechanism and broadly neutralizing antibodies guide structure-based vaccine design.Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin Mice.Prospecting for an HIV vaccine.Virus-like Particles Identify an HIV V1V2 Apex-Binding Neutralizing Antibody that Lacks a Protruding Loop.Priming HIV-1 broadly neutralizing antibody precursors in human Ig loci transgenic mice Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo.Glycans Function as Anchors for Antibodies and Help Drive HIV Broadly Neutralizing Antibody Development.Elicitation of Neutralizing Antibodies Targeting the V2 Apex of the HIV Envelope Trimer in a Wild-Type Animal Model.HIV Envelope Glycoform Heterogeneity and Localized Diversity Govern the Initiation and Maturation of a V2 Apex Broadly Neutralizing Antibody Lineage.

P2860

Q26765966-C4CECBDD-9F4F-4FCE-84EE-A264551AD55B Q27644544-59D48814-F39B-468A-A3BA-3B6BFE553CF8 Q27704710-6728C8A7-544F-40B5-9F88-B44AFE7F1BE4 Q27723297-722EF565-6B18-48E9-807B-3E8F06C17E21 Q28554907-E117764A-D8AB-4361-B3D8-954325AE6C67 Q28729792-E615301D-ECE4-4233-A5E8-E18EA7FF2033 Q30234773-55853610-20E5-45A5-832B-C2DB54FAA5B2 Q30352300-1AE484F4-BB89-4E35-88C4-9E40AF96D6C4 Q33592001-EED11D06-2635-4131-828A-CD9B4360D5C1 Q36157560-A768568D-D8DC-4525-B79E-12B71E7BC843 Q36263513-4688EB69-FBA1-427F-A5E0-BD19E7B9845E Q36290038-4A0CB890-3695-41EE-937C-00690689139A Q37021717-DBFB8966-FFA3-4BF3-B436-A73B27A57079 Q37069837-140F2947-2328-458F-B936-1B60B4F197B0 Q37246321-6E75D7DA-1110-4E7F-A317-83100AD2CE0B Q37271866-9121A096-B526-490D-B2F6-31E4DA5C455A Q37293480-C873EFBE-84D0-4C53-BFA3-9FB3BF448E9F Q37300461-B39BA013-DBDA-4425-87C6-766C80A8433B Q37417794-372571BD-6EBD-4C14-B285-317A79FC7EEE Q37469648-D06D2F10-AD21-4E96-A89E-BD91819880A6 Q37621530-01189680-6203-425E-AC93-4888758CBD59 Q37633417-8FBC0C37-9D29-4FFC-82A6-782C17D82ABF Q37634061-7233331E-2D09-417B-AA05-D4549DF405F7 Q38764547-45FC3315-DEE7-433B-8DD1-5D1987B57E10 Q38862338-99C1607C-F391-4F01-B2CF-1BF346A6BC33 Q38936867-550552C2-369A-4A83-B07C-35BFB0566E03 Q38992740-BB2B3809-7087-4651-879E-6237F9DFF2F0 Q39108740-80B68F1C-34BD-4885-963C-EA1BB72001F6 Q39108751-9B30A776-90D6-40D5-AEDA-BA868E6A63A8 Q39108796-5AED73BB-2D27-41B9-BDEA-2F27497916C3 Q39170404-D1B1153D-995E-4946-8E98-145F5639C562 Q39250593-3778093C-706A-4546-AF40-4A008D4EB1E1 Q39407795-FEDF9A9A-861D-48C6-8012-6F7B4AF420FC Q40051921-8FD922E3-1D6D-4A49-AB54-1E175BE08CD2 Q40198060-EA78876A-CDCF-4127-9CEA-3DA619C4D49F Q40589505-E584141A-B1B0-48C0-A442-F4AD0D269E2D Q41611835-97F7952C-BEC6-4034-9121-5E9136BDF26C Q41936503-1F014155-46D5-45E6-8FBA-BD69D497FD8A Q42377340-0E5F5AF6-C8EB-4143-B4CB-7211F1ACAF13 Q46454115-A27B69B2-1865-4D9A-B8F0-1E06239344D5

P2860

Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal commonalities that enable vaccine design

http://www.wikidata.org/entity/Q27644634

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@ast

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@en

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@nl

type

label

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@ast

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@en

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@nl

prefLabel

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@ast

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@en

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@nl

P1433

Q27644634-BE2AE765-ADB6-4277-8F6C-7962B628034D

P1476

Q27644634-6F7AC1F3-B809-4873-A1F2-343BEE26AFE7

P2093

Q27644634-03143E03-84B2-4E4A-A2BC-6926D190023F

Q27644634-0D5E0A15-C522-4047-A536-67A13F936EE8

Q27644634-0E78E106-18B1-4E5E-B9B1-1DAB02E7AEF6

Q27644634-0F70ACDA-E4D5-4B1C-8D4C-D8D5C4741C95

Q27644634-175FBEC1-DC90-4141-A99B-C4C235C94628

Q27644634-1B15B327-0F50-4CD7-9D0D-39ABB73F01E4

Q27644634-1DED94F2-B918-4BD9-B64A-A77006E62151

Q27644634-22A196FF-1333-4F4D-B8D1-E4A462BF2F7B

Q27644634-255C0FBB-EBFF-4A67-A5C8-57FE59D3CBA6

Q27644634-333DC375-7F9B-42EB-8206-5EB766030D76

P2860

Q27644634-06047E5D-F931-4545-A71B-EAA3D09F07EF

Q27644634-064CD6D4-9CCC-4AB4-B348-A8A160114E2C

Q27644634-09656620-85F2-429B-9660-CA7E82612EDF

Q27644634-09A0BD20-2C66-473D-B063-FF46038D8F33

Q27644634-0BD2DBB2-D685-4A96-A06B-38E70CEAC068

Q27644634-0FABBADE-AB5A-4613-8152-591F0CB74841

Q27644634-1224DB08-2F72-417E-B2A8-0CCCEAE7C7CD

Q27644634-127CCBC2-74BC-4AFD-84AB-B8398315D83F

Q27644634-15926FFA-B75D-4B94-9BDB-02CDDFD2DDD8

Q27644634-15E10E0B-C8E7-45D5-8BA7-3A95BEE727C8

P2888

Q27644634-BF00A3D9-A3E6-4223-B058-04F54816033E

P304

Q27644634-4A9A0ABD-8C06-4F8D-975D-834EAB818F50

P31

Q27644634-A672A412-A439-4A3B-B91C-CFC44D4F8A2E

P3181

Q27644634-20507D76-0696-4651-982C-08050D42A3B7

P356

Q27644634-39DFCF7A-71E6-4E87-94F0-A61B5E978B38

P433

Q27644634-EAD6AD6D-B5D2-49BE-A822-BE458EE8B86A

P478

Q27644634-E5BA217D-E117-437E-9062-99251705DFC8

P50

Q27644634-02C0B121-9874-4198-9B0D-3F1A9EE5F37E

Q27644634-061389B7-651B-4CE0-9831-9F4C3B6A83AC

Q27644634-0F9089E6-5D3D-4B40-9A2C-971D517A5E19

Q27644634-1AB3390F-046A-4F68-ACB8-8893E0745B14

Q27644634-240DC77B-B1E0-4857-B176-7EED49AE47C1

Q27644634-397A9D01-19CB-4DE2-BBA8-BF572ACFCAEC

Q27644634-5360232F-3918-4EE1-B071-2F72B3F1375D

Q27644634-5EEE7883-C822-4BE1-988A-68847ED7FB64

Q27644634-BEBF9320-45B4-449E-ACFF-2983206C8A12

Q27644634-C96F9F02-DC7C-4DE2-9A4B-1D9BB00D3B39

P577

Q27644634-27B384FD-3272-495A-90E7-BD5A9F486ABB

P6179

Q27644634-92928D45-D280-4F42-98B5-E457C937276E

P698

Q27644634-16409005-A484-4BEA-B366-B30038B56CF0

P921

Q27644634-10F07EEC-7084-427F-B12F-3BA256191BD1

Q27644634-835E36D4-B30E-413D-9F21-37DCD18C8FE2

P932

Q27644634-04570ECC-C467-4EBC-987A-1CAAF2DC0514

P3181

P356

P1433

Nature Structural & Molecular Biology

P1476

Structures of HIV-1 Env V1V2 w ...... ies that enable vaccine design

@en

P2093

Adrian B McDermott

http://www.w3.org/2001/XMLSchema#string

Aliaksandr Druz

http://www.w3.org/2001/XMLSchema#string

Baoshan Zhang

http://www.w3.org/2001/XMLSchema#string

Brandon J DeKosky

http://www.w3.org/2001/XMLSchema#string

George Georgiou

http://www.w3.org/2001/XMLSchema#string

Gwo-Yu Chuang

http://www.w3.org/2001/XMLSchema#string

Ivelin S Georgiev

http://www.w3.org/2001/XMLSchema#string

Jonathan Stuckey

http://www.w3.org/2001/XMLSchema#string

Kelly K Lee

http://www.w3.org/2001/XMLSchema#string

M Gordon Joyce

http://www.w3.org/2001/XMLSchema#string

P2860

Structural definition of a conserved neutralization epitope on HIV-1 gp120

Processing of X-ray diffraction data collected in oscillation mode

Designed protein G core variants fold to native-like structures: Sequence selection by ORBIT tolerates variation in backbone specification

Unusual binding properties of the SH3 domain of the yeast actin-binding protein Abp1: structural and functional analysis

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Enhancing protein crystallization through precipitant synergy

Structural Repertoire of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors

Crystal structure, conformational fixation and entry-related interactions of mature ligand-free HIV-1 Env

Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

P2888

P304

81-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3092591

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/NSMB.3144

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Lawrence Shapiro

Michael Chambers

Jonathan R McDaniel

James C Mullikin

P577

2016-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1048836415

http://www.w3.org/2001/XMLSchema#string

P698

26689967

http://www.w3.org/2001/XMLSchema#string

P921

structural biology

P932

4833398

http://www.w3.org/2001/XMLSchema#string